ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines across Europe, Canada, and Australia, has completed the purchase of the commercial rights to Testoviron® from Bayer for Europe and selected markets in Latin America, the Middle East & Africa, and Asia-Pacific.
Testoviron® is a long-acting injectable testosterone used to treat male hypogonadism*. Adding the brand strengthens ADVANZ PHARMA’s specialty portfolio and leverages its commercial and medical operations in Europe and global partner network.
The transaction builds on existing agreements between ADVANZ PHARMA and Bayer. Financial terms are not being disclosed.
